Text Size

Integrase Inhibitor (MK-0518) Viral Decay

This study has been completed.
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Canadian Immunodeficiency Research Collaborative
ClinicalTrials.gov Identifier:
NCT00520897
First received: August 24, 2007
Last updated: June 4, 2012
Last verified: June 2012
History of Changes
  Purpose

The eradication of HIV by antiretroviral therapy has thus far been elusive. It has been consistently demonstrated that a pool of latently infected, resting CD4+ T cells persists in the majority of HIV-infected individuals receiving antiretroviral therapy in whom plasma viremia has been successfully suppressed for prolonged periods of time; this pool has emerged as the major obstacle in achieving the eradication of HIV. We believe that MK-0518 can further the decay and suppression of HIV-1 in patients who have been virologically suppressed for a prolonged period of time on effective cART (≥ 4 years).


Condition Intervention Phase
HIV Infections
 Drug: Raltegravir (MK0518)
Drug: Placebo
Procedure: Leukopheresis
Procedure: Sigmoid Biopsy
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Integrase Inhibitor (MK-0518) on Decay of Low Level Viral Replication in HIV Reservoirs in Infected Individuals Who Initiated Conventional Antiretroviral Therapy During the Chronic Phase of Infection

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Canadian Immunodeficiency Research Collaborative:

Primary Outcome Measures:
  • change of proviral HIV-1 DNA in total CD4+ T cells from baseline to week 48 [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    evaluate the change of proviral HIV-1 DNA in total CD4+ T cells from baseline to week 48 in participants randomized to the raltegravir arm (400mg raltegravir) for 48 weeks in addition to their current standard combination antiretroviral regimen versus the control arm, who remained on their current standard combination antiretroviral regimen.


Secondary Outcome Measures:
  • evaluated the effect of raltegravir intensification on blood CD4+ T cell populations [ Time Frame: 48 & 96 weeks ] [ Designated as safety issue: No ]
    evaluated the effect of raltegravir intensification on blood CD4+ T cell populations. In addition, after treatment-intensification in both groups at week 48, a post-hoc follow-up of all participants was conducted up to week 96 to examine if raltegravir intensification had any long-term effects on proviral HIV DNA and CD4+ T cell populations in the blood and gut.


Enrollment: 24
Study Start Date: April 2007
Study Completion Date: November 2011
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MK0518 + cART
Raltegravir + standard of care combined antiretroviral therapy
 Drug: Raltegravir (MK0518)
400mg BID; 48 weeks
Procedure: Leukopheresis
pack of cells as per protocol
Procedure: Sigmoid Biopsy
gut samples as per protocol
Placebo Comparator: Placebo + cART
Placebo + standard of care combined antiretroviral therapy
 Drug: Placebo
400mg QD
Procedure: Leukopheresis
pack of cells as per protocol
Procedure: Sigmoid Biopsy
gut samples as per protocol

Detailed Description:

The trial is a prospective, double-blind, randomized, placebo-controlled study with two phases: phase I to 48 weeks and phase II to 96 weeks with the primary analysis at 48 weeks. HIV-infected individuals who are taking their first standard cART regimen for at least four years with complete viral suppression. Upon enrollment, he/she will be randomized to one of two arms: the MK-0518 arm or the control arm. As each participant reaches week 48, he/she will be unblinded and those in the MK-0518 arm will continue taking MK-0518. Based on the results of an interim analysis, the control arm will be rolled over to receive MK-0518 for 48 weeks. After the screening, baseline visits and week 4 safety visit, follow-up visits will occur every 8 weeks for both arms.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participant must be HIV-1 infected
  2. Participant must be 18 years old
  3. Participant must be taking first standard cART with 2-3 NRTIs and 1-2 PIs or an NNRTI for at least four years (first cART regimen may include changes due to toxicity but not due to virologic failure).
  4. Participant must have a VL < 50 copies/ml (using the standard available methods of detection) during the entire time on standard cART except for initial fall of VL and a maximum of two non-consecutive blips of < 100 copies/ml that the study investigator deems to be not clinically significant
  5. Female participant must agree to use two methods of birth control or abstinence during the period of the study
  6. Participant has to have signed full informed consent

Exclusion Criteria:

  1. Participant who would have difficulty participating in a trial due to non-adherence or substance abuse
  2. Participant who has taken mono or dual antiretroviral therapy in the past
  3. Participant who has had a VL > 50 copies/ml on any antiretroviral regimen

  4. Participant with any of the following abnormal laboratory test results in screening:

    • Hemoglobin < 100 g/L
    • Neutrophil count < 750 cells/L
    • Platelet count < 50,000 cells/L
    • AST or ALT > 5X the upper limit of normal
    • Creatinine > 250 mol/L
  5. Participant with a malignancy
  6. Participant with other significant underlying disease (non-HIV) that might impinge upon disease progression or death
  7. Participant with an active AIDS-defining illness in the past six months
  8. Participant who is pregnant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00520897

Locations
Canada, Ontario
Maple Leaf Medical Clinic
Toronto, Ontario, Canada, M5B 1L6
Sponsors and Collaborators
Canadian Immunodeficiency Research Collaborative
National Institutes of Health (NIH)
Investigators
Principal Investigator: Mona Loutfy, MD Women's College Hospital
  More Information

No publications provided

Responsible Party: Canadian Immunodeficiency Research Collaborative
ClinicalTrials.gov Identifier: NCT00520897     History of Changes
Other Study ID Numbers: 038-00
Study First Received: August 24, 2007
Last Updated: June 4, 2012
Health Authority: Canada: Health Canada

Keywords provided by Canadian Immunodeficiency Research Collaborative:
chronic HIV infection
Human Immunodeficiency Virus
Treatment Experienced

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
 Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013